Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: Testing the equivalence margins between dabigratran, rivaroxaban and apixaban

European Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2014, Pages 505-506

  Messori, Andrea ^a,b   Maratea, Dario ^a   Fadda, Valeria ^a   Trippoli, Sabrina ^a  

^a ESTAV Toscana Centro   (Italy)

^b HTA Unit Area Vasta Centro Toscana Regional Health System   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ATTRIBUTABLE RISK; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; META ANALYSIS (TOPIC); PATIENT INFORMATION; POST HOC ANALYSIS; PRIORITY JOURNAL; ANIMAL; ATRIAL FIBRILLATION; CHEMICALLY INDUCED;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; INTRACRANIAL HEMORRHAGES;

EID: 84896488039     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1644-7     Document Type: Letter

References (8)

1. Lip GY, Larsen TB, Skjøth F, Rasmussen LH (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60(8):738-746
2. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ (2013) New oral anticoagulants and the risk of intracranial hemorrhage: traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. doi:10.1001/jamaneurol.2013. 4021.
3. ArrudaMA (2013) No evidence of efficacy or evidence of no efficacy. JAMA Pediatr 167(3):300-302
4. Witte S, Victor N (2004) Some problems with the investigation of noninferiority in meta-analysis. Methods Inf Med 43(5):470-474 (Pubitemid 40040327)
5. Ahn S, Park SH, Lee KH (2013) How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology 267(2):328-338
6. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C (2013) Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis. Clin Infect Dis 57(12): 1783-1784
7. CADTH (2013) Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation [Internet]. Canadian Agency for Drugs and Technologies in Health [cited 2013 Nov 7]. Available from: http://www.cadth.ca/en/products/therapeuticreviews/antithrombotic-therapy/ reports
8. Wisløff T, Ringerike T, Hagen G, Reikvam Å, Klemp M (2013) Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation - report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services), No 5-2013, Health Technology Assessment. Available from: http://www. kunnskapssenteret.no/publikasjoner/efficacy-and-cost-effectiveness-of-new-oral- anticoagulants-compared-to-warfarin-for-the-prevention-of-stroke-in-patients- with-atrial-fibrillation?language=english